VOSTALLY
LaunchSMramipril
NDAORALSOLUTION
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Angiotensin-converting Enzyme Inhibitors
Pharmacologic Class:
Angiotensin Converting Enzyme Inhibitor
Clinical Trials (5)
Ramipril for the Treatment of COVID-19
Started May 2020
160 enrolled
COVID-19
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
Started Jun 2019
295 enrolled
Myocardial Infarction
A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril
Started Jan 2018
16 enrolled
Diabetes MellitusHealthy Subjects
REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial
Started Oct 2015
168 enrolled
HypertensionHigh Blood Pressure Variability
Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers
Started Jan 2011
23 enrolled
Healthy
Loss of Exclusivity
LOE Date
Aug 16, 2039
163 months away
Patent Expiry
Aug 16, 2039
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 12343338 | Aug 16, 2039 | Product | U-4233 |